Axsome Therapeutics (AXSM *) Stock Overview
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AXSM * Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Axsome Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,519.00 |
| 52 Week High | US$1,519.00 |
| 52 Week Low | US$1,190.00 |
| Beta | 1.25 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 115.46% |
| 5 Year Change | n/a |
| Change since IPO | 141.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| AXSM * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -3.2% |
| 1Y | n/a | 3.4% | 17.7% |
Return vs Industry: Insufficient data to determine how AXSM * performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AXSM * performed against the MX Market.
Price Volatility
| AXSM * volatility | |
|---|---|
| AXSM * Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in MX Market | 6.4% |
| 10% least volatile stocks in MX Market | 2.2% |
Stable Share Price: AXSM *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine AXSM *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 589 | Herriot Tabuteau | www.axsome.com |
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder.
Axsome Therapeutics, Inc. Fundamentals Summary
| AXSM * fundamental statistics | |
|---|---|
| Market cap | Mex$79.53b |
| Earnings (TTM) | -Mex$5.98b |
| Revenue (TTM) | Mex$5.65b |
Is AXSM * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXSM * income statement (TTM) | |
|---|---|
| Revenue | US$291.49m |
| Cost of Revenue | US$28.26m |
| Gross Profit | US$263.23m |
| Other Expenses | US$571.78m |
| Earnings | -US$308.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.43 |
| Gross Margin | 90.30% |
| Net Profit Margin | -105.85% |
| Debt/Equity Ratio | 174.4% |
How did AXSM * perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/15 15:49 |
| End of Day Share Price | 2024/07/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Axsome Therapeutics, Inc. is covered by 33 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |